Cannon Gillian 4

What Happened
Gillian Cannon, a director of Xenon Pharmaceuticals (XENE), sold 1,190 shares on June 5, 2026 in an open-market transaction at $53.14 per share, generating proceeds of approximately $63,237. This was a sale (not a purchase) and appears tied to routine tax-related actions rather than an opportunistic trade.

Key Details

• Transaction date and price: 2026-06-05 — 1,190 shares sold at $53.14 each. Total proceeds ≈ $63,237.
• Method: Open-market sale reported as code "S".
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Footnote: Sale was executed pursuant to a Rule 10b5-1 trading plan adopted Aug 15, 2025, solely to satisfy income tax obligations related to RSUs that vested on June 5, 2025.
• Filing timeliness: Form 4 filed on 2026-06-08 for the 2026-06-05 transaction — appears timely.

Context
Sales executed under prearranged 10b5-1 plans for tax withholding are common and generally viewed as routine (they do not necessarily signal the insider’s view on the company). For retail investors, purchases typically carry more informational weight than planned sales; this transaction primarily reflects tax-related liquidity.